- South Korea
- /
- Biotech
- /
- KOSDAQ:A086890
ISU Abxis Co., Ltd.'s (KOSDAQ:086890) Intrinsic Value Is Potentially 84% Above Its Share Price
Key Insights
- Using the 2 Stage Free Cash Flow to Equity, ISU Abxis fair value estimate is ₩11,269
- ISU Abxis' ₩6,130 share price signals that it might be 46% undervalued
- Analyst price target for A086890 is ₩8,000 which is 29% below our fair value estimate
In this article we are going to estimate the intrinsic value of ISU Abxis Co., Ltd. (KOSDAQ:086890) by projecting its future cash flows and then discounting them to today's value. Our analysis will employ the Discounted Cash Flow (DCF) model. Don't get put off by the jargon, the math behind it is actually quite straightforward.
Companies can be valued in a lot of ways, so we would point out that a DCF is not perfect for every situation. If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model.
View our latest analysis for ISU Abxis
The Calculation
We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second 'steady growth' period. To start off with, we need to estimate the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.
Generally we assume that a dollar today is more valuable than a dollar in the future, so we need to discount the sum of these future cash flows to arrive at a present value estimate:
10-year free cash flow (FCF) forecast
2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | |
Levered FCF (₩, Millions) | ₩7.50b | ₩9.97b | ₩12.4b | ₩14.5b | ₩16.4b | ₩18.0b | ₩19.4b | ₩20.6b | ₩21.6b | ₩22.6b |
Growth Rate Estimate Source | Analyst x1 | Est @ 32.99% | Est @ 23.86% | Est @ 17.47% | Est @ 13.00% | Est @ 9.87% | Est @ 7.67% | Est @ 6.14% | Est @ 5.07% | Est @ 4.31% |
Present Value (₩, Millions) Discounted @ 6.7% | ₩7.0k | ₩8.8k | ₩10.2k | ₩11.2k | ₩11.9k | ₩12.2k | ₩12.3k | ₩12.3k | ₩12.1k | ₩11.8k |
("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = ₩110b
The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (2.6%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 6.7%.
Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = ₩23b× (1 + 2.6%) ÷ (6.7%– 2.6%) = ₩560b
Present Value of Terminal Value (PVTV)= TV / (1 + r)10= ₩560b÷ ( 1 + 6.7%)10= ₩293b
The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is ₩403b. In the final step we divide the equity value by the number of shares outstanding. Compared to the current share price of ₩6.1k, the company appears quite good value at a 46% discount to where the stock price trades currently. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind.
The Assumptions
Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. If you don't agree with these result, have a go at the calculation yourself and play with the assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at ISU Abxis as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 6.7%, which is based on a levered beta of 0.876. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
SWOT Analysis for ISU Abxis
- Debt is well covered by .
- Interest payments on debt are not well covered.
- Shareholders have been diluted in the past year.
- Expected to breakeven next year.
- Trading below our estimate of fair value by more than 20%.
- Debt is not well covered by operating cash flow.
- Has less than 3 years of cash runway based on current free cash flow.
Next Steps:
Valuation is only one side of the coin in terms of building your investment thesis, and it shouldn't be the only metric you look at when researching a company. It's not possible to obtain a foolproof valuation with a DCF model. Instead the best use for a DCF model is to test certain assumptions and theories to see if they would lead to the company being undervalued or overvalued. For example, changes in the company's cost of equity or the risk free rate can significantly impact the valuation. Why is the intrinsic value higher than the current share price? For ISU Abxis, we've compiled three important factors you should further examine:
- Risks: You should be aware of the 1 warning sign for ISU Abxis we've uncovered before considering an investment in the company.
- Future Earnings: How does A086890's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
- Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!
PS. Simply Wall St updates its DCF calculation for every South Korean stock every day, so if you want to find the intrinsic value of any other stock just search here.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About KOSDAQ:A086890
ISU Abxis
A biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide.
Flawless balance sheet and slightly overvalued.